Both Eressa and Troche are lung cancer molecularly targeted therapeutics, which are small molecule compounds targeting epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). It is generally considered that Eressa is advantageous for use in women, adenocarcinoma (especially alveolar cell carcinoma), Asian patients without a history of smoking, especially those with molecular biologically confirmed exon 18, 19, 20 and 21 mutations of EGFR, and even considered as first-line therapy in Asian women with extensively metastatic lung adenocarcinoma, while in men, Troche is recommended. The most common side effects of Erythromycin are diarrhea, rash, itchy skin, others are impaired liver function, nausea and vomiting, but most of them are mild in degree and can be relieved with symptomatic management. In addition, interstitial pneumonia occurs in a very small number of patients. The efficacy of Erythromycin can generally be initially evaluated after 1 month of administration. If it is effective, it should be continued for a long time until tumor progression occurs before considering discontinuation or adjustment. Troche is a targeted therapy drug that has been shown to significantly prolong the survival of lung cancer patients. It can also be used in combination with chemotherapy, e.g., troche in combination with gemcitabine resulted in significantly longer progression-free survival, was well tolerated, and did not increase hematopoietic adverse effects. The most common adverse reactions to trospium are rash, diarrhea, decreased appetite, fatigue, dry skin, pruritus, and rarely, severe interstitial lung disease (ILD). At present, there is a switch to troche after resistance to Iridium use, or troche is used first and ineffective and then Iridium is used, although it can be observed that very few patients also become effective, but the maintenance of effective time is generally not long.